Efficacy and safety of low-dose rifabutin-based 7-day triple therapy as a third- or later-line Helicobacter pylori eradication regimen

Inokuchi, K; Mori, H; Matsuzaki, J; Hirata, K; Harada, Y; Saito, Y; Suzuki, H; Kanai, T; Masaoka, T

Masaoka, T (通讯作者),Keio Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.

HELICOBACTER, 2022; 27 (4):

Abstract

Background Rifabutin-based regimens are used as rescue therapy for refractory Helicobacter pylori infection; however, the duration for which treatment......

Full Text Link